News & Updates
Filter by Specialty:
Novel drug helps optimize HFrEF therapy
27 Apr 2022
byAudrey Abella
In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.